Drug | Proliferation | Viability1-a | Apoptosis | PPARγ1-b | IC501-c | COX-1/COX-2 Ratio | |
---|---|---|---|---|---|---|---|
COX-1 | COX-2 | ||||||
μM | μM | μM | |||||
Troglitazone | ↓1-e | 28.3 | ↑1-g | 1.1 | N.T. | N.T. | N.T. |
15dPGJ2 | ↓ | 6.6 | ↑ | 0.8 | N.T. | N.T. | N.T. |
Indometacin | ↓ | 113.5 | ↑ | 54.7 | 0.013 | 0.044 | 0.30 |
Diclofenac | ↓ | 59.7 | ↑ | 28.9 | 0.037 | 0.00097 | 38 |
Oxaprozin | ↓ | 166.7 | ↑ | 45.5 | 2.2 | 36 | 0.061 |
Zaltoprofen | ↓ | 135.2 | ↑ | 54.5 | 1.3 | 0.34 | 3.8 |
Ketoprofen | →1-f | >300 | N.T. | >100 | 0.11 | 0.88 | 0.80 |
Acetaminophen | → | >300 | N.T. | >100 | 421-d | 111-d | 3.81-d |
NS-398 | ↓ | >300 | → | >100 | 12 | 0.0095 | 1263 |
N.T., not tested.
↵1-a IC50 values for inhibition of cell viability.
↵1-b Concentration at which the drugs exhibit a 25-fold induction of the activation of PPARγ over the untreated condition in the luciferase reporter assay.
↵1-c IC50 values for inhibition of COX-1 and COX-2 by NSAIDs were cited from the reference byKawai et al. (1998).
↵1-d IC50 values for inhibition of COX-1 and COX-2 by acetaminophen were cited from the reference byCryer et al. (1998).
↵1-e Decrease.
↵1-f No change.
↵1-g Increase.